Gossamer Bio(GOSS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - SAN DIEGO—(BUSINESS WIRE)— November 7, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinicalstage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (P ...